Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dynamiker Biotechnology (Tianjin) Co EBITDA Margin %?
Dynamiker Biotechnology (Tianjin) CoBJSE:920009 46 EBITDA Margin % is 37.44% as of Mar. 2026, which is 6% below its 10-year median of 40.01. GuruFocus rates BJSE:920009 with a GF Score™ of 46/100. The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Dynamiker Biotechnology (Tianjin) Co ranks better than 94.36% on this metric.
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dynamiker Biotechnology (Tianjin) Co EBITDA Margin % Related Terms
Dynamiker Biotechnology (Tianjin) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynamiker Biotechnology (Tianjin) Co EBITDA Margin % Chart
BJSE:920009 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynamiker Biotechnology (Tianjin) Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) has a EBITDA Margin % of 37.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dynamiker Biotechnology (Tianjin) Co and its competitors. This is near median its historical median of 40.01. Over the past decade, Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin % has ranged from 23.81 to 49.59. According to the industry distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #54 out of 957 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin % too high?
Dynamiker Biotechnology (Tianjin) Co's current EBITDA Margin % of 37.44% is near median its 10-year median of 40.01. Over the past 10 years, this metric has ranged from a low of 23.81 to a high of 49.59. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Dynamiker Biotechnology (Tianjin) Co's value of 37.44% is 209.2% above this industry median. Based on the distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #54 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dynamiker Biotechnology (Tianjin) Co has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Dynamiker Biotechnology (Tianjin) Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #54 out of 957 companies for EBITDA Margin %. This places Dynamiker Biotechnology (Tianjin) Co in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.11. Dynamiker Biotechnology (Tianjin) Co's value of 37.44% is 209.2% above this benchmark. Historically, Dynamiker Biotechnology (Tianjin) Co's own EBITDA Margin % has ranged from 23.81 to 49.59 over the past decade. While the company's 10-year median is 40.01 vs. the industry median of 12.11, Dynamiker Biotechnology (Tianjin) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynamiker Biotechnology (Tianjin) Co's current EBITDA Margin % of 37.44% is 209.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dynamiker Biotechnology (Tianjin) Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynamiker Biotechnology (Tianjin) Co's current EBITDA Margin % is 37.44%, which is near median its own 10-year median of 40.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynamiker Biotechnology (Tianjin) Co stock overvalued right now?
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) has a current EBITDA Margin % of 37.44%. The current EBITDA Margin % is 37.44%, which is near median its 10-year median of 40.01 and 209.2% above the Drug Manufacturers industry median of 12.11. Dynamiker Biotechnology (Tianjin) Co's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dynamiker Biotechnology (Tianjin) Co (BJSE:920009), the current EBITDA Margin % is 37.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dynamiker Biotechnology (Tianjin) Co Ltd specializes in R&D, production, and sales of early serological diagnosis of invasive mycosis and in vitro diagnostic products for other pathogenic microorganisms.
46GF Score
Get the complete analysis for BJSE:920009
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920009 has been successfully added to your 
